

Supporting Information

Tandem Elimination-Oxidation of Tertiary Benzylic Alcohols with an Oxoammonium Salt

*Rowan I. L. Meador, Robert E. Anderson and John D. Chisholm**

Department of Chemistry, Syracuse University, 1-014 Center for Science and Technology

Syracuse, NY 13244

jdchisho@syr.edu


Contents

Table of Contents	S1
Experimental Procedures and Tabulated NMR Data	S2-S4
NMR Spectra	S5-S16
References	S17


General Experimental Information

All anhydrous reactions were run under a positive pressure of argon. DCM (DCM) was dried by passage through an alumina column.¹ 1,2-Dichloroethane (DCE) was freshly distilled from calcium hydride before use. Silica gel column chromatography was performed using 60 Å silica gel (230–400 mesh). Melting points are uncorrected. The benzylic alcohols used in the study were prepared as reported in the literature.²


General procedure for allylic oxidation: To a solution of 0.33 mmol of alkene (1 equiv) in acetonitrile (0.33 M), 4 Å molecular sieves was added. The flask was put under an atmosphere of argon. Then 0.40 mmol of *N*-oxoammonium salt (1.2 equiv) was added in one portion. The flask was purged with argon. The reaction mixture was left to stir at room temperature for 6 hours. The reaction was quenched with saturated aqueous bicarbonate solution, extracted with ethyl acetate (3x), and washed with brine (3x). The organic layers were combined, dried over sodium sulfate, and concentrated. The residue was purified by silica chromatography to give the product.



***N*-{2,2,6,6-Tetramethyl-1-[(1-methylidene-3,4-dihydro-2H-naphthalen-2-yl)oxy]piperidin-4-yl}acetamide (3).** Followed general procedure. Purified by silica chromatography using a solvent gradient of 50–70%. EA/hexanes to give product as an off-white solid. When scaled up to 6 mmol obtained 1.32 g of product. Yield: 60%. IR (film): 3246, 3073, 2969, 1633, 1363, 777 cm⁻¹; TLC R_f = 0.30 (70% EA/30% hexanes); mp = 143–145 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.48–7.46 (m, 1H), 7.11–7.01 (m, 3H), 5.44 (s, 1H), 5.25 (bs, 2H), 4.43 (t, J = 4.63 Hz, 1H), 4.06–4.02 (m, 1H), 3.08–3.00 (m, 1H), 2.69 (dt, J = 16.7, 5.4, 1H), 2.07–2.03 (m, 2H), 1.86 (s, 3H), 1.75–1.72 (m, 1H), 1.63 (dt, J = 12.3, 3.6 Hz, 1H), 1.30–1.24 (m, 1H), 1.19–1.17 (m, 7H), 0.97 (s, 3H), 0.87 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 169.3, 144.5, 136.4, 134.3, 128.7, 127.5, 126.0, 125.0, 110.6, 82.0, 60.3, 59.8, 46.3, 46.1, 41.7, 34.4, 34.2, 29.4, 26.2, 23.6, 21.2, 21.0; Anal Calcd for C₂₂H₃₂N₂O₂: C, 74.12; H, 9.05; N, 7.86; Found: C, 73.56; H, 9.01; N, 7.75.




***N*-(1-[(1Z)-1-Ethylidene-3,4-dihydro-2H-naphthalen-2-yl]oxy)-2,2,6,6-tetramethylpiperidin-4-yl acetamide (8).** Followed general procedure. Purified by silica chromatography using a solvent gradient of 50–70%. EA/hexanes to give 0.070 g product as a white solid. Yield: 57%. IR (film) 3254, 3091, 2921, 1637, 1374, 952, 769 cm⁻¹; TLC R_f = 0.31 (70% EA/30% hexanes); mp = 141–143 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.36–7.34 (m, 1H), 7.06–7.00 (m, 3H), 5.96 (q, J = 6.7 Hz, 1H), 5.09 (d, J = 6.7 Hz, 1H), 4.91 (bs, 1H), 4.03–3.95 (m, 1H), 3.12–3.04 (m, 1H), 2.63 (dd, J = 16.5, 5.4 Hz, 1H), 2.28–2.25 (m, 1H), 1.87–1.86 (m, 3H), 1.85 (s, 3H), 1.75–1.59 (m, 5H), 1.26 (s, 3H), 1.15 (s, 3H), 0.80 (s, 3H), 0.78 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 169.2, 137.6, 136.1, 135.5, 128.5, 126.4, 125.9, 124.6, 121.7, 74.8, 60.6, 59.1, 46.4, 46.1, 41.2, 33.8, 33.6, 28.8, 24.8, 23.6, 20.9, 20.7, 14.5; Anal Calcd for C₂₃H₃₄N₂O₂: C, 74.55; H, 9.25; N, 7.56; Found: C, 74.34; H, 9.30; N, 7.25. Alkene geometry was determined to be Z via NOESY NMR.




***N*-(1-[(1Z)-1-Butylidene-3,4-dihydro-2H-naphthalen-2-yl]oxy)-2,2,6,6-tetramethylpiperidin-4-yl acetamide (10).** Followed general procedure. Purified by silica chromatography using a solvent gradient of 50–70%. EA/hexanes to give 0.075 g product as an oil. Yield: 56%. IR (film) 3272, 2925, 2868, 1640, 1550, 1373, 1362, 777 cm⁻¹; TLC R_f = 0.32 (70% EA/30% hexanes); ¹H NMR (400 MHz, CDCl₃) δ 7.54–7.42 (m, 1H), 7.13–7.07 (m, 3H), 5.93 (t, J = 7.4 Hz, 1H), 5.33 (d, J = 7.2 Hz, 1H), 4.94 (s, 1H), 4.14–4.01 (m, 1H),


3.19-3.11 (m, 1H), 2.69 (dd, $J = 5.6, 16.4$ Hz, 1H), 2.46-2.39 (m, 1H), 2.27-2.25 (m, 2H), 1.91 (s, 3H), 1.81-1.72 (m, 3H), 1.67-1.64 (m, 1H), 1.58-1.42 (m, 3H), 1.31 (s, 3H), 1.22 (s, 3H), 0.96 (t, $J = 7.2$ Hz, 3H), 0.87 (s, 3H), 0.83 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.2, 136.8, 136.2, 135.7, 128.5, 127.8, 126.4, 125.9, 124.8, 75.1, 60.6, 59.1, 46.4, 46.1, 41.2, 33.9, 33.7, 30.8, 28.9, 24.8, 23.6, 23.0, 20.9, 20.7, 14.1; Anal Calcd for $\text{C}_{25}\text{H}_{38}\text{N}_2\text{O}_2$: C, 75.33; H, 9.61; N, 7.03; Found: C, 75.31; H, 9.50; N, 6.87.




N-[2,2,6,6-Tetramethyl-1-[(1-methylidene-2,3-dihydroinden-2-yl)oxy]piperidin-4-yl]acetamide (14). Followed general procedure. Purified by silica chromatography using a solvent gradient of 50-70% EA/hexanes to give 0.061 g product as a solid. Yield: 53%. IR (film) 3267, 2924, 1637, 1362, 732 cm^{-1} ; TLC $R_f = 0.23$ (70% EA/30% hexanes); mp = 150-153 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.45-7.43 (m, 1H), 7.21 (s, 3H), 5.55 (d, $J = 1.7$ Hz, 1H), 5.42 (s, 1H), 5.22 (d, $J = 6.9$ Hz, 1H), 5.11 (t, $J = 6.9$ Hz, 1H), 4.21-4.12 (m, 1H), 3.22 (dd, $J = 7.5, 15.5$ Hz, 1H), 3.06 (dd, $J = 6.8, 15.5$ Hz, 1H), 1.95 (s, 3H), 1.83-1.81 (m, 2H), 1.38-1.34 (m, 5H), 1.27-1.23 (m, 9H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.2, 149.7, 142.1, 139.1, 128.7, 126.9, 125.2, 120.8, 105.9, 87.1, 61.0, 59.5, 46.4, 46.3, 41.1, 38.7, 34.5, 33.0, 23.6, 21.2, 21.0; Anal Calcd for $\text{C}_{21}\text{H}_{30}\text{N}_2\text{O}_2$: C, 73.65; H, 8.83; N, 8.18; Found: C, 73.62; H, 8.55; N, 7.80.



N-[2,2,6,6-Tetramethyl-1-({5-methylidene-6,7,8,9-tetrahydrobenzo[7]annulen-6-yl)oxy}piperidin-4-yl]acetamide (16). Followed general procedure. Purified by silica chromatography using a solvent gradient of 50-70% EA/hexanes to give 0.058 g product as an oil. Yield: 47%. IR (film) 3267, 3081, 2971, 1636, 1550, 1362, 778 cm^{-1} ; TLC $R_f = 0.23$ (70% EA/30% hexanes); ^1H NMR (400 MHz, CDCl_3) δ 7.20-7.13 (m, 3H), 7.07-7.06 (m, 1H), 5.31 (s, 1H), 5.18 (d, $J = 3.8$ Hz, 1H), 5.07 (s, 1H), 4.31 (bs, 1H), 4.14-4.07 (m, 2H), 2.79-2.69 (m, 2H), 2.21 (bs, 1H), 2.13-2.03 (m, 2H), 1.92 (s, 4H), 1.79-1.68 (m, 3H), 1.29-1.23 (m, 2H), 1.20 (s, 4H), 1.16 (s, 2H), 1.12 (s, 2H), 1.09 (s, 2H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.4, 153.6, 141.6, 140.1, 129.0, 128.6, 127.1, 126.0, 112.9, 86.2, 60.6, 59.4, 46.3, 41.0, 37.5, 35.9, 34.8, 34.6, 33.8, 23.9, 23.5, 21.1, 20.9; Anal Calcd for $\text{C}_{23}\text{H}_{34}\text{N}_2\text{O}_2$: C, 74.55; H, 9.25; N, 7.56; Found: C, 74.34; H, 9.30; N, 7.25.




N-[2,2,6,6-Tetramethyl-1-[(2-phenylprop-2-en-1-yl)oxy]piperidin-4-yl]acetamide (18). Followed general procedure. Purified by silica chromatography using a solvent gradient of 50-70% EA/hexanes to give product as colorless oil. Yield: 45%. IR (film) 3273, 3081, 2973, 1633, 1550, 705 cm^{-1} ; TLC $R_f = 0.26$ (70% EA/30% hexanes); ^1H NMR (400 MHz, CDCl_3) δ 7.34-7.12 (m, 5H), 5.38 (s, 1H), 5.33 (s, 1H), 5.19 (bs, 1H), 4.57 (s, 1H), 4.09-4.04 (m, 1H), 1.88-1.71 (m, 5H), 1.29-1.23 (m, 3H), 1.16-1.15 (m, 12H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.3, 144.2, 139.4, 128.3, 127.6, 126.0, 112.7, 78.4, 60.13, 45.8, 41.1, 32.9, 23.6, 20.9; Anal Calcd for $\text{C}_{20}\text{H}_{30}\text{N}_2\text{O}_2$: C, 72.69; H, 9.15; N, 8.48; Found: C, 72.48; H, 8.79; N, 8.46.




N-[1-[(7-Chloro-1-methylidene-3,4-dihydro-2H-naphthalen-2-yl)oxy]-2,2,6,6-tetramethylpiperidin-4-yl]acetamide (24). Followed general procedure. Purified by silica chromatography using a solvent gradient of 50-70% EA/hexanes to give 0.062 g product as a white solid. Yield: 48%. IR (film) 3255, 2970, 1634, 1362 cm^{-1} ; TLC $R_f = 0.25$ (70% EA/30% hexanes); mp = 102-105 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.50 (d, $J = 2.1$ Hz, 1H), 7.13 (dd, $J = 2.1, 8.2$ Hz, 1H), 7.04 (d, $J = 8.2$ Hz, 1H), 5.51 (s, 1H), 5.28 (s, 1H), 5.14 (d, $J = 6.9$ Hz, 1H), 4.49 (d, $J = 3.5$ Hz, 1H), 4.15-4.07 (m, 1H), 3.11-3.03 (m, 1H), 2.75-2.68 (m, 1H), 2.17-2.14 (m, 1H),


2.07-2.03 (m, 1H), 1.93 (s, 3H), 1.89- 1.69 (m, 4H), 1.24 (m, 6H), 1.03 (s, 3H), 0.91 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.3, 143.4, 135.9, 134.8, 131.7, 130.1, 127.5, 124.8, 112.1, 81.6, 60.5, 59.8, 46.2, 46.1, 41.1, 34.5, 34.2, 29.1, 25.5, 23.6, 21.2, 20.9; Anal calcd for $\text{C}_{22}\text{H}_{31}\text{ClN}_2\text{O}_2$: C, 67.59; H, 7.99; N, 7.17; Found: C, 67.26; H, 8.02; N, 7.33.





N-{1-[(7-Bromo-1-methylidene-3,4-dihydro-2H-naphthalen-2-yl)oxy]-2,2,6,6-tetramethylpiperidin-4-yl} acetamide (26). Followed general procedure. Purified by silica chromatography using a solvent gradient of 50-70%. EA/hexanes to give 0.065 g product as a yellow solid. Yield: 45%. IR (film) 3270, 2928, 1640, 1555, 731 cm^{-1} ; TLC $R_f = 0.22$ (70% EA/30% hexanes); mp = 140-144 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.66 (d, $J = 1.8$ Hz, 1H), 7.27 (d, $J = 10.0$ Hz, 1H), 6.97 (d, $J = 8.0$ Hz, 1H), 5.50 (s, 1H), 5.28 (s, 1H), 5.17 (bs, 1H), 4.49 (bs, 1H), 4.11 (bs, 1H), 3.09-3.01 (m, 1H), 2.72-2.68 (m, 1H), 2.15-2.13 (m, 1H), 2.07-2.03 (m, 1H). 1.93 (s, 3H), 1.81 (d, $J = 11.6$ Hz, 1H), 1.71 (d, $J = 11.9$ Hz, 1H), 1.25-1.23 (m, 8H), 1.03 (s, 3H), 0.91 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.4, 143.3, 136.3, 135.3, 130.4, 130.3, 127.8, 119.7, 112.2, 81.6, 60.5, 59.8, 46.2, 46.1, 41.1, 34.5, 34.1, 29.0, 25.6, 23.6, 21.2, 20.1; Anal calcd for $\text{C}_{22}\text{H}_{31}\text{BrN}_2\text{O}_2$: C, 60.69; H, 7.18; N, 6.43; Found: C, 60.53; H, 6.93; N, 6.14.






N-{1-[(7-Cyano-1-methylidene-3,4-dihydro-2H-naphthalen-2-yl)oxy]-2,2,6,6-tetramethylpiperidin-4-yl} acetamide (28). Followed general procedure. Purified by silica chromatography using a solvent gradient of 50-70%. EA/hexanes to give 0.051 g product as a tan solid. Yield: 40%. IR (film) 3291, 2974, 2932, 1661, 1516, 902, 723 cm^{-1} ; TLC $R_f = 0.20$ (70% EA/30% hexanes); mp = 153-157 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.74 (s, 1H), 7.35 (d, $J = 7.7$ Hz, 1H), 7.13 (d, $J = 7.7$ Hz, 1H), 5.48 (s, 1H), 5.27 (s, 1H), 5.12 (d, $J = 5.9$ Hz, 1H), 4.45 (d, $J = 3.0$ Hz, 1H), 4.06-4.02 (m, 1H), 3.14-3.06 (m, 1H), 2.77-2.70 (m, 1H), 2.18-2.14 (m, 1H), 1.97-1.95 (m, 1H), 1.87 (s, 3H), 1.76-1.61 (m, 3H), 1.31-1.23 (m, 1H), 1.19 (s, 3H), 1.16 (s, 3H), 0.91 (s, 3H), 0.79 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.3, 142.7, 141.9, 135.5, 130.3, 129.6, 129.2, 119.2, 113.4, 110.0, 81.4, 60.6, 59.7, 46.1, 46.0, 41.1, 34.6, 34.1, 28.6, 26.1, 23.6, 21.1, 20.1; Anal calcd for $\text{C}_{23}\text{H}_{31}\text{N}_3\text{O}_2$: C, 72.41; H, 8.19; N, 11.01; Found: C, 72.49; H, 8.16; N, 10.67.





1-Methylene-3,4-dihydro-2(2H)-naphthalene (29). In an oven dried round-bottom flask, 0.734 g (11.2 mmol, 10 equiv) of zinc powder was added and suspended in 18 mL ether (0.62 M). The zinc powder was activated with 0.099 g (0.896 mmol, 0.8 equiv) TMSCl. The reaction was refluxed for 30 minutes. After 30 minutes, the zinc suspension was cooled to room temperature and the ether was evaporated. A solution of 0.400 g (1.12 mmol) the ACT ether **3** was dissolved in 14.4 mL 1:1 AcOH:H₂O (0.08 M) and added drop wise to the activated zinc. The reaction was heated to 45 °C and left to stir for 2 h. After 2 h the reaction was cooled to room temperature, diluted with water and extracted with ether (3x). The organic layers were combined, dried over magnesium sulfate, and concentrated. The residue was purified by silica chromatography (30% ether/pentanes) to give 0.088 g product as an oil. Yield: 49%. TLC $R_f = 0.32$ (30% ether/70% pentane); ^1H NMR (400 MHz, CDCl_3) δ 7.58-7.55 (m, 1H), 7.18-7.04 (m, 3H), 5.54 (s, 1H), 5.23 (s, 1H), 4.45 (dd, $J = 3.2$, 7.6 Hz, 1H), 3.00 (dt, $J = 6.4$, 16.2 Hz, 1H), 2.80 (dt, $J = 6.4$, 16.9 Hz, 1H), 2.04-1.87 (m, 2H); $^{13}\text{C}\{\text{H}\}$ NMR (75 MHz, CDCl_3) δ 146.2, 136.2, 132.8, 128.9, 128.0, 126.2, 124.9, 108.5, 70.9, 31.4, 26.3. This compound has been previously reported.³

















NOESY spectra of Allylic Ether **8**


























7.739
7.736
7.370
7.350
7.346
7.194
7.144
7.124
5.479
5.268
5.190
5.111
4.467
4.461
4.453
4.447
4.059
4.048
4.038
4.028
4.018
4.007
3.996
3.141
3.127
3.114
3.098
3.083
3.069
3.066
2.771
2.760
2.746
2.728
2.716
2.702
2.178
2.169
2.155
2.148
2.137
1.964
1.952
1.945
1.933
1.927
1.896
1.798
1.759
1.750
1.736
1.728
1.718
1.657
1.648
1.639
1.626
1.617
1.608
1.307
1.301
1.271
1.240
1.228
1.219
1.187
1.162
1.127
0.95
0.823
0.791
0.756





-169.284

142.726
141.949
135.489
130.338
129.645
129.215
119.226
113.400
110.050
81.384
77.336
77.279
77.079
76.758
60.580
59.671
46.153
46.054
41.085
34.600
34.097
29.707
28.563
26.146
23.575
21.115
20.910





-146.246
-136.164
-132.242
-129.553
-129.011
-129.244
-124.976
-108.463
-77.475
-77.055
-76.631
~70.911



References

- 1) Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Safe and Convenient Procedure for Solvent Purification. *Organometallics* **1996**, *15*, 1518-1520.
- 2) Kelley, B. T.; Walters, J. C.; Wengryniuk, S. E. Access to Diverse Oxygen Heterocycles via Oxidative Rearrangement of Benzylic Tertiary Alcohols. *Org. Lett.* **2016**, *18*, 1896-1899.
- 3) Banks, H.; Ziffer, H. Effect of ring size and methyl substituents on lithium bromide-catalyzed rearrangements of aryloxiranes. *J. Org. Chem.* **1982**, *47*, 3743-3747.